UPC Analytics
DEEN
Übersicht · Eingereicht:

CC_65201/2024

FLUID DELIVERY DEVICE WITH TRANSCUTANEOUS ACCESS TOOL, INSERTION MECHANISM AND BLOOD GLUCOSE MONITORING FOR USE THEREWITH

VerletzungWiderklage auf VerletzungMilan CDCounterclaim for infringement
Parteien

Kläger

  • Insulet Corporation
Vertreter: Frank Peterreins (Peterreins Schley Patent- und Rechtsanwälte)

Beklagte

  • EOFLOW Co., Ltd.
Vertreter: Christopher Pierce (Hoyng Rokh Monegier)
Richter
  • Andrea PostiglionePresiding Judge and Judge-Rapporteur
  • Anna-Lena KleinLegally Qualified Judge
  • Uwe SchwengelbeckTechnically Qualified Judge
Patente
  • EP 4 201 327
CPC-Codes: A61M5/1723, A61M5/1452, A61M5/158, A61B5/14865, A61M5/14244, F04B9/02, A61B5/14532, A61M2230/201, A61M2005/14506, A61M5/14248, B65D83/761, A61M5/3291

Technologiebereich: Medical Devices · Continuous Glucose Monitoring

Sektor: Packaging & Conveying

Ausgang
VerletztVerletzt
Eingereicht:
Erste Entscheidung: 22. Juli 2025
Sprache:

The Milan Central Division issued a landmark decision finding infringement of EP 4 201 327 (Insulet Corporation) by EOFLOW Co., Ltd. by default on the counterclaim for infringement, following EOFLOW's failure to defend. The court also decided by default on the revocation action (finding insufficient grounds for revocation) and resolved costs of the preliminary injunction proceedings. The court ordered EOFLOW to cease and desist from infringing activities across all UPC contracting member states, recall products from the market, remove products from channels of commerce, destroy infringing products, and provide full information on the extent of infringement. The court applied a unitary approach to cost caps where two parallel proceedings concerned the same patent and infringement acts.

Ansprüche
Streitigall
Aufrechterhaltenall
Verletztall
Hinweise: Milan Central Division found EOFLOW infringed EP 4 201 327 by default and dismissed EOFLOW's revocation action; patent maintained; no specific claim numbers enumerated in excerpt.